Johnson & Johnson spotlights nipocalimab at FMF Congress 2024 – the first and only FcRn blocker to be studied in maternal fetal diseases

LISBON (June 24, 2024)– Johnson & Johnson (NYSE: JNJ) today announced that seven presentations featuring the Company’s research in maternal-fetal immunology will be shared at the Fetal Medicine Foundation World Congress 2024. Data presentations will highlight the Company’s continued evaluation of nipocalimab for the potential treatment of pregnant individuals with hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT). When completed, this research will further define the unmet needs in these rare conditions caused by placental transfer of alloantibodies which pose significant risk to the fetus or newborn. “We are deeply committed to research with a goal of providing safe treatment options that address the underlying causes and serious health consequences associated with HDFN and FNAIT – two diseases for which there are no approved therapeutic options,” said Katie Abouzahr, M.D., Vice President, Autoantibody Portfolio and Maternal Fetal Immunology Disease Area Leader, Johnson & Johnson. “There is an ongoing need for continued innovation in maternal fetal immunology with the aim of delivering safe and effective therapies for these diseases.” Data presentation highlights: Showcasing research in HDFN and FNAIT Abstract Name Hemolytic disease of the fetus and newborn Management and outcomes in hemolytic disease of the fetus and newborn: a systematic literature review Nipocalimab pharmacodynamics in a Phase 2 study in pregnancies at risk of early-onset severe hemolytic disease of the fetus and newborn (HDFN) Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN Fetal and neonatal alloimmune thrombocytopenia Design of a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of nipocalimab in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia (FREESIA-1) Allele frequencies for the most common antigens that cause alloimmunization in FNAIT, HPA-1a and HPA-5b, are similar across diverse populations Both conditions SF-36v2afor assessment in HDFN or FNAIT-affected pregnancies - results of a landscape assessment and clinician and patient interviews in the US Mixed methods research to understand disease burden and unmet need in HDFN and FNAIT Ongoing commitment to maternal-fetal immunology · Johnson & Johnson is committed to working with the maternal-fetal immunology community, patients and families to advance research to help address diseases that affect pregnant populations o J&J Innovative Medicine will be hosting a booth with more information on its efforts across the maternal-fetal space. Enrollment in a Johnson & Johnson maternal-fetal clinical trial · TheAZALEA pivotal Phase 3 trialis currently enrolling pregnant individuals who are at risk of a severe HDFN pregnancy · TheFREESIA pivotal Phase 3 trialis currently enrolling patients who are at risk of an FNAIT pregnancy Editor’s Note: a. SF-36v2 is a short-form health survey that measures each of the following eight health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These factors are used to assess the quality of life and functional health and well-being of patients across a variety of health conditions. ABOUT HDFN Hemolytic disease of the fetus and newborn (HDFN) is a rare disease (and in its severe form, ultra rare) that arises in pregnancies with maternal-fetal incompatibility in certain red blood cell types.1Alloantibodies produced by the maternal immune system against fetal red blood cells cross the placenta during pregnancy and attack fetal red blood cells causing fetal anemia or persist after birth in the neonate to cause neonatal hyperbilirubinemia and anemia.2The symptoms of HDFN can range from mild jaundice, to neurotoxic hyperbilirubinemia in the newborn, to life-threatening fetal anemia requiring invasive intervention.3The potential for in utero onset at an increasingly earlier GA with increasing risk of severe outcomes may occur with each incompatible pregnancy due to pregnancy-related alloimmunization.4Currently there are no non-surgical interventions approved for pregnancies at high risk for severe HDFN.5Pregnancies affected by severe HDFN may necessitate repeated intrauterine transfusions (IUTs), which are invasive, technically complex surgical procedures performed by specialists at specialized medical centers, and these procedures are associated with an increased rate of fetal mortality and premature birth.6,7,8The most difficult to treat cases of HDFN are early onset severe HDFN (EOS-HDFN) that develops at ≤24 weeks gestational age (GA) and results in significant fetal/neonatal morbidity and mortality.According to theAmerican Journal of Obstetrics and Gynecology, in the U.S., it is estimated that up to 80 of every 100,000 pregnancies are affected by HDFN each year.9 ABOUTFNAIT Fetal neonatal alloimmune thrombocytopenia (FNAIT) is a rare and potentially life-threatening alloimmune condition in which a pregnant person’s immune system develops alloantibodies against fetal or newborn platelet antigens, leading to thrombocytopenia (low platelet counts) in the fetus or newborn.10 FNAIT can result in severe bleeding complications for a fetus or newborn and is characterized by organ bleeding in the gastrointestinal tract, lungs, or eyes.10 If a severe bleed occurs in the brain, termed intracranial hemorrhage (ICH), death or life-long neurologic effects may occur.10ICH occurs in up to 26 percent of untreated pregnancies with FNAIT.11 It has an estimated incidence rate of 1 in 1000 pregnancies.10,12There are no approved therapies for the treatment of FNAIT. Because FNAIT is not routinely screened for during pregnancy, the diagnosis of an affected FNAIT pregnancy often occurs postnatally.10 ABOUT NIPOCALIMAB Nipocalimab is an investigational monoclonal antibody, purposefully designed to bind with high affinity to block FcRn and reduce levels of circulating immunoglobulin G (IgG) antibodies, while preserving immune function without causing broad immunosuppression. This includes autoantibodies and alloantibodies that underlie multiple conditions across three key segments in the autoantibody space including Rare Autoantibody diseases, Maternal Fetal diseases mediated by maternal alloantibodies and Prevalent Rheumatology.13,14,15,16,17,18,19,20,21Blockade of IgG binding to FcRn in the placenta is also believed to prevent transplacental transfer of maternal alloantibodies to the fetus.22 ,23 The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted several key designations to nipocalimab including: · Fast Track designation in HDFN and warm autoimmune hemolytic anemia (wAIHA) in July 2019, gMG in December 2021 and FNAIT in March 2024 · Orphan drug status for wAIHA in December 2019, HDFN in June 2020, gMG in February 2021, chronic inflammatory demyelinating polyneuropathy CIDP in October 2021 and FNAIT in December 2023 · Breakthrough Therapy designation for HDFN by the FDA in February 2024 · Orphan medicinal product designation for HDFN by the EMA in October 2019 ABOUT JOHNSON & JOHNSON At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more athttps://www.jnj.com/or atwww.janssen.com/johnson-johnson-innovative-medicine. Follow us at@JanssenUSand@JNJInnovMed. Janssen Research & Development, LLC and Janssen Biotech, Inc. are Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of nipocalimab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online atwww.sec.gov,www.jnj.comor on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc, nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. # # # 1Hemolytic disease of the newborn. Medline Plus. Accessed: November 18, 2022.https://medlineplus.gov/ency/article/001298.htm 2National Library of Medicine. Hemolytic Diseases of the Newborn. StatPearls Publishing. 2023 Jan. Available at:https://www.ncbi.nlm.nih.gov/books/NBK557423/. Accessed: June 2024. 3Ree IMC, Smits-Wintjens VEHJ, van der Bom JG, et al. Neonatal management and outcome in alloimmune hemolytic disease, Expert Review of Hematology, 10:7, 607-616, doi: 10.1080/17474086.2017.1331124. Accessed: June 2024. 4Lobato G, Soncini CS. Relationship between obstetric history and Rh(D) alloimmunization severity. Arch Gynecol Obstet. 2008 Mar;277(3):245-8. Doi: 10.1007/s00404-007-0446-x. Accessed: June 2024. 5DeMoss, P., Asfour, M. and Hersey, K. Anti-K1 (Kell) antibody expressed in maternal breastmilk: A case report of a neonate with multiple intrauterine transfusions and postnatal exposure to Kell antibody in maternal breastmilk’, Case reports in pediatrics. 2017. Doi:10.1155/2017/6927813. Accessed: June 2024. 6Texas Children’s Hospital. Intrauterine Transfusion. Available at:https://women.texaschildrens.org/program/texas-childrens-fetal-center/procedures-offered/intrauterine-transfusion. Accessed: June 2024. 7de Winter DP, Kaminski A, et al. Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape. BMC Pregnancy and Childbirth. 2023;23(12). Doi:https://doi.org/10.1186/s12884-022-05329-z. Accessed: June 2024. 8Lindenburg IT, van Kamp IL, van Zwet EW, Middeldorp JM, Klumper FJ, Oepkes D. Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation. BJOG. 2013 Jun;120(7):847-52. doi: 10.1111/1471-0528.12063. 9Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program. (2015) 2015(1):146-151. doi:https://doi.org/10.1182/asheducation-2015.1.146. Accessed: June 2024. 10NORD. Fetal and Neonatal Alloimmune Thrombocytopenia. Published online July 2022.https://rarediseases.org/rare-diseases/fetal-and-neonatal-alloimmune-thrombocytopenia/. Accessed June 2024. 11Constantinescu S, Zamfirescu V, Vladareanu PR. Fetal and neonatal alloimmune thrombocytopenia. Maedica (Bucur). 2012 Dec;7(4):372-6. PMID: 23482913; PMCID: PMC3593293. 12Lieberman L, Greinacher A, Murphy M, et al. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. British Journal of Haematology. Volume 185, Issue 3. May 2019. Pages 549-562. 13ClinicalTrials.gov. NCT03842189. Available at:https://clinicaltrials.gov/ct2/show/NCT03842189. Accessed: June 2024 14ClinicalTrials.gov Identifier: NCT04951622. Available at:https://clinicaltrials.gov/study/NCT04951622. Accessed: June 2024. 15ClinicalTrials.gov Identifier: NCT05327114. Available at:https://www.clinicaltrials.gov/study/NCT05327114. Accessed: June 2024 16ClinicalTrials.gov Identifier: NCT04119050. Available at:https://clinicaltrials.gov/study/NCT04119050. Accessed: June 2024. 17ClinicalTrials.gov Identifier: NCT05379634. Available at:https://clinicaltrials.gov/study/NCT05379634. Accessed: June 2024. 18ClinicalTrials.gov Identifier: NCT05912517. Available at:https://www.clinicaltrials.gov/study/NCT05912517. Accessed: June 2024 19ClinicalTrials.gov Identifier: NCT06028438. Available at:https://clinicaltrials.gov/study/NCT06028438. Accessed: June 2024. 20ClinicalTrials.gov Identifier: NCT04968912. Available at:https://clinicaltrials.gov/study/NCT04968912. Accessed: June 2024. 21ClinicalTrials.gov Identifier: NCT04882878. Available at:https://clinicaltrials.gov/study/NCT04882878. Accessed: June 2024. 22Lobato G, Soncini CS. Relationship between obstetric history and Rh(D) alloimmunization severity. Arch Gynecol Obstet. 2008 Mar;277(3):245-8. DOI: 10.1007/s00404-007-0446-x. Accessed: June 2024 23Roy S, Nanovskaya T, Patrikeeva S, et al. M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model. Am J Obstet Gynecol. 2019;220(5):498 e491-498 e499. Media contact: Bridget Kimmel Mobile: +1 215 688-6033 [email protected] Investor contact: Raychel Kruper [email protected] Discover J&J News Our Credo & our purpose Leadership Social impact Suppliers Our history Policies & reports Environmental sustainability Medicines & therapies Products Oncology Immunology Neuroscience Cardiopulmonary Medical devices & technology Products Cardiovascular Orthopaedics Surgery Vision About us Our company Medicines & therapies Medical devices & technology Careers Investors Media Key links Terms of use Privacy Cookie policy Customize cookie settings Digital Accessibility Statement Get in touch Contact Socials linkedin instagram facebook twitter This website is intended for U.S. audiences only. Do not sell or share my personal information Limit the use of my sensitive personal information © Johnson & Johnson and its affiliates 2026

The release as fetched from its publisher. jnj.com ↗